A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study
Latest Information Update: 20 May 2025
At a glance
- Drugs Brensocatib (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- Acronyms The BiRCh Study
- Sponsors Insmed
Most Recent Events
- 08 May 2025 Status changed to active, no longer recruiting, according to an Insmed media release
- 20 Feb 2025 According to Insmed media release, the topline data is expected in end of 2025.
- 10 Jan 2025 According to Insmed media release, the study has completed nearly 70% of its target enrollment. Topline data continue to be expected before the end of 2025.